Mobile
Search
Advanced search
Multi-criteria search
Who are we ?
Log in
Sign up
Français
English
Kusajili – Clinical trials directory
Result
of your search per sponsor: Novartis Pharma
Woman and Man Max 99 years
Novartis Pharma Services AG
Update Il y a 4 ans
Safety and efficacy of osilodrostat (LCI699) for the treatment of patients with Cushing's disease
To compare the complete response rate at the end of the 8-week period of randomized withdrawal (Week 34) between patients randomized to continued LCI699 therapy vs. placebo.
Country
None
organs
None
Specialty
None
unknown
More information
Woman and Man Max 99 years
Novartis Pharma S.A.S
Update Il y a 4 ans
Etude prospective, randomisée, en ouvert évaluant le bénéfice clinique sur les hypoglycémies après 6 mois de l’addition de la vildagliptine versus celle d’un autre antidiabétique oral, chez des patients âgés diabétiques de type 2, insuffisamment contrôlés par la metformine en monothérapie
L’objectif principal est de comparer dans les deux groupes de traitement, le pourcentage de patients n’ayant présenté aucune hypoglycémie (épisodes confirmés par automesure de la glycémie capillaire o...
Country
None
organs
None
Specialty
None
Closed trial
More information
Woman and Man Max 99 years
Novartis Pharma Service AG
Update Il y a 4 ans
A phase IIIb, open-label, multi-center 12 month study to evaluate the safety, tolerability and efficacy of ranibizumab (0.3 and/or 0.5 mg) in patients with subfoveal choroidal neovascularization secondary to age-related macular degeneration
The primary objective of this study is to estimate the incidence of ocular adverse events (AEs) in patients with CNV secondary to AMD who are treated with 0.3 and/or 0.5 mg intravitreal ranibizumab.
Country
None
organs
None
Specialty
None
Closed trial
More information
Woman and Man Max 99 years
Novartis Pharma Services AG
Update Il y a 4 ans
Study of safety and efficacy of EGF816 in combination with INC280 in non-small cell lung cancer patients with EGFR mutation
Phase Ib part: To estimate the MTD or RP2D of EGF816 in combination with INC280 Phase II part: To estimate the preliminary anti-tumor activity of EGF816 in combination with INC280
Country
None
organs
None
Specialty
None
unknown
More information
Woman and Man Max 99 years
Novartis Pharma GmbH
Update Il y a 4 ans
Study to compare a tacrolimus Hexal® based regimen versus a Prograf® based regimen in renal transplantation
PHASE I: To demonstrate that the pharmacokinetics of Tacrolimus Hexal® assessed by the ratio of the AUC0-12h over a one month period post-transplantation is comparable to Prograf® in renal transplant...
Country
None
organs
None
Specialty
None
Closed trial
More information
Woman and Man Max 99 years
Novartis Pharma Services AG
Update Il y a 4 ans
A randomized, multi center, parallel group, double-blind, placebo and formoterol controlled 14 day dose ranging trial 4 doses of indacaterol delivered via Twisthaler®, in patients with COPD
125, 250, and 500 μg o.d.) and placebo as measured by the mean change from baseline to 24 hr post-dose (trough) FEV1 after 14 days of treatment. (Baseline FEV1 is defined as the average of two FEV1 as...
Country
None
organs
None
Specialty
None
Closed trial
More information
Woman and Man Max 99 years
Novartis Pharmaceuticals Japan
Update Il y a 4 ans
Dose Ranging Study of Indacaterol in Japanese Patients With Chronic Obstructive Pulmonary Disease (COPD)
The study was designed to obtain data about the efficacy and safety of 3 doses of indacaterol (150, 300, and 600 µg) in Japanese patients with chronic obstructive pulmonary disease (COPD) ...
Country
None
organs
None
Specialty
None
Closed trial
More information
Woman and Man Max 99 years
Novartis Pharma Services AG
Update Il y a 4 ans
Assessment of the safety and efficacy of intravenous (10mg/kg) and subcutaneous (300mg) secukinumab in moderate to severe chronic plaque-type psoriasis who are partial responders to secukinumab
Efficacy of intravenous administration of secukinumab compared with subcutaneous administration of secukinumab with respect to both PASI 75 and IGA 0 or 1 response
Country
None
organs
None
Specialty
None
Closed trial
More information
Woman and Man Max 99 years
Novartis Pharma Services AG
Update Il y a 4 ans
A 24 week, randomized, double blind, multicenter, placebo-controlled efficacy, safety, tolerability and PK trial of Nilotinib (AMN107) in Pulmonary Arterial Hypertension (PAH)
• To evaluate the effect of nilotinib on pulmonary vascular resistance (PVR) compared to placebo after 24 weeks of therapy
Country
None
organs
None
Specialty
None
Closed trial
More information
Woman
Between 18 years and 60 years
Novartis Pharma
Update Il y a 6 ans
Étude MONALEESA-7 : étude de phase 3, randomisée, évaluant un traitement associant ribociclib (LEE011) ou un placebo au tamoxifène (ou un inhibiteur d’aromatase non stéroïdien (IANS)) et à la goséréline, chez des femmes pré-ménopausées atteintes d’un cancer du sein à récepteurs hormonaux positifs (HR+), HER2-négatif (HER2-), à un stade avancé.
Le cancer du sein est très fréquent chez les femmes mais peu apparaissent chez les femmes de moins de 40 ans alors qu’il est plus sévère. Le traitement hormonal est une option de traitement standard ...
Country
France
organs
Sein
Specialty
None
Essai ouvert aux inclusions
More information
Previous
6
7
8
9
10
11
12
13
14
15
Next